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Wecomparedvaginalproinﬂammatorycytokineandsecretoryleukocyteproteaseinhibitor(SLPI)concentrationsamongpregnant
and nonpregnant women according to bacterial vaginosis (BV) status. One-hundred and twenty-two women at 12–20 weeks’
gestation and 133 nonpregnant controls had vaginal concentrations of interleukin (IL)-1β,I L - 6 ,I L - 8 ,a n dS L P Im e a s u r e db y
enzyme immunoassay. Multivariable linear regression was used to evaluate factors independently associated with vaginal cytokine
and SLPI response. Pregnancy and BV were both independently associated with increased vaginal concentrations of IL-1β and
IL-8; pregnant women had increased concentrations of SLPI, while women with BV had decreased SLPI concentrations.
1.Introduction
Ascending bacterial infection is an important antecedent
of preterm birth, which continues to be a major cause of
neonatal mortality. Bacterial vaginosis (BV) is a common
vaginal condition that reﬂects a shift from the normal
Lactobacillus predominant vaginal ﬂora to a vaginal ﬂora
characterized by high concentrations of anaerobic bacteria.
BV is consistently associated with preterm birth [1, 2];
however,antibiotic treatmenttrialsforBVinpregnancyhave
not reduced preterm birth [3], leading to speculation that
the maternal and/or fetal host response may be implicated
inthepathophysiologyofinfection-associatedpretermbirth.
We sought to evaluate the relationships between pregnancy,
BV and their eﬀects on the vaginal inﬂammatory response
by comparing the vaginal concentrations of interleukin (IL)-
1β, IL-6, IL-8 and the host defense molecule secretory
leukocyte protease inhibitor (SLPI) among pregnant and
nonpregnant women according to BV status. We hypoth-
esized that pregnant and nonpregnant women would have
similar proinﬂammatory cytokine and SLPI concentrations
in vaginal ﬂuid, when stratiﬁed by BV status.
2.MaterialsandMethods
We compared vaginal cytokine concentrations among
women with and without BV enrolled in two separate
prospective observational cohort studies. Pregnant subjects’
data came from a natural history study of vaginal ﬂora
and pregnancy outcome, conducted from 2000–2004, in
Seattle, Washington. Pregnant women <20 weeks’ gestation,
≥16 years of age, with no history of preterm birth or
major medical complications such as chronic hypertension
or preexisting diabetes, were eligible to participate. Non-
pregnant subjects’ data came from a cohort study of racial
disparities in preterm birth conducted between 2002–2006.
Study participants were parous women ≥18 years of age
who resided and gave birth in King County, Washington,
and did not have a history of preeclampsia or hypertensive
disorders. By design, the nonpregnant cohort oversampled
African-American subjects. The pregnancy cohort study was
approved by the University of Washington and Centers for
Disease Control Institutional Review Boards. The nonpreg-
nant cohort study was approved by the Washington State
Department of Health Institutional Review Board. Written2 Journal of Pregnancy
informed consent was obtained from all subjects at the time
of entry into the original cohorts.
Bothcohortshadidenticalmethodsforsamplecollection
and processing. Participants were asked to abstain from
vaginal intercourse for 2 days prior to their enrollment
visit. Participants completed a brief questionnaire about
demographics, medical history, and risk behaviors. Urine or
vaginal ﬂuid was collected for Chlamydia trachomatis and
Neisseria gonorrhoeae testing by nucleic acid ampliﬁcation
test (Aptima Combo 2; Gen-Probe, San Diego, CA). Vaginal
ﬂuid was collected from the posterior vaginal fornix using
four Dacron swabs (Puritan Hardwood Products, Guilford,
Maine). One swab was rolled on a glass slide for Gram
stain for BV diagnosis by Nugent criteria [4], the second
was placed in culture media for Trichomonas vaginalis testing
(InPouch TV; Biomed Diagnostics, White City, Oregon),
and the third and fourth swabs were placed in cryotubes
with 0.9mL of phosphate buﬀered saline. These swabs were
frozen at −80◦C until assayed. Interleukin-1β, IL-6, IL-8,
and SLPI were measured by enzyme linked immunosorbent
assay (ELISA) at the same laboratory [5]. Acid phosphatase,
a sensitive marker for semen, was detected by colorimetric
method using an azo dye. Any specimens testing positive for
acid phosphotase were excluded from SLPI analysis as SLPI
can be found in high concentrations in seminal ﬂuid [6, 7].
Subjects were included in the analysis if they had
complete data for the following variables: BV status, IL-
1β, IL-6, IL-8, SLPI, and sexually transmitted disease (STD)
results (C. trachomatis, N. gonorrhoeae and T. vaginalis).
Women with intermediate ﬂora (Nugent score 4–6) or
who tested positive for C. trachomatis, N. gonorrhoeae,o r
T. vaginalis were excluded from the analysis. Among 289
womeninthepregnancycohortwithnormalﬂoraorBV,246
women (86%) had samples available for proinﬂammatory
cytokinetesting.Ofthe246womenwithcytokineresults,118
(48%) women were missing one or more STD results (101 of
118 were missing T. vaginalis results; 98 of the 101 women
had normal vaginal ﬂora) and 6 women tested positive for
an STD (4 C. trachomatis and 2 T. vaginalis). Thus 122
pregnant women, 71 with BV (Nugent score 7–10) and 51
with normal vaginal ﬂora (Nugent score 0–3), had complete
information and were included in the analysis. Among 159
women in the nonpregnant cohort with normal ﬂora or BV,
147women(92%)hadsamplesavailableforcytokinetesting.
Two nonpregnant women were missing STD results and 12
women tested positive for an STD (4 C. trachomatis and 8 T.
vaginalis), leaving 133 nonpregnant women, 45 with BV and
86 with normal vaginal ﬂora in the analysis.
Chi-squared and Mann-Whitney U tests were used
to compare demographic characteristics at baseline. The
Mann-Whitney U test was also used for univariate analyses
to compare analyte concentrations by BV and pregnancy
status. Proinﬂammatory cytokine and SLPI values were
not normally distributed and were log10-transformed for
analysis.Meanlog-transformedcytokinevaluesandstandard
deviationswerecalculatedbyBVandpregnancystatus.Addi-
tional analyses were conducted using multivariable linear
regression to evaluate BV and pregnancy as independent fac-
tors associated with cytokine and SLPI response (adjusting
for race and age). Lastly, we evaluated an interaction term
for BV and pregnancy using the likelihood ratio test. This
interaction term was not signiﬁcantly associated with
cytokine or SLPI response and was not included in the ﬁnal
models for each analyte. All statistical tests were assessed
using a 2-sided alpha of 0.05. Analyses were conducted using
Stata version 10.1 (StataCorp, Inc., College Station, TX).
3. Results
Nonpregnant women were older (mean age = 29.2 years
(range 18–46) versus 26.7 years (range 16–43) P = .005),
more often African-American (44% versus 20%, P<. 001)
and more likely to report ever douching (61% versus 19%,
P<. 001), and current smoking (34% versus 16%, P = .001)
compared to pregnant women.
In univariate analyses, pregnant women had higher
concentrations of IL-1β (mean log-transformed values ±
standard deviation: 1.94±0.86 versus 1.43±0.92pg/mL; P<
.001), IL-6 (0.63 ± 0.60 versus 0.50 ± 0.40pg/mL; P = .002),
and IL-8 (3.20 ± 0.76 versus 2.88 ± 0.80pg/mL; P = .003)
compared to nonpregnant women. Among pregnant and
nonpregnant women combined, those with BV had higher
concentrationsofIL-1β (2.11±0.85versus1.31±0.83pg/mL;
P<. 001) and IL-8 (3.15 ± 0.88 versus 2.85 ± 0.71pg/mL;
P = .004) compared to women without BV. Concentrations
of IL-6 did not diﬀer signiﬁcantly by BV status (BV+: 0.64 ±
0.66 versus BV-: 0.50 ± 0.57pg/mL; P = .09). The highest
concentrations of IL-1β and IL-8 were found in the subset
of pregnant women with BV, compared to all other subjects
(IL-1β:2 .31 ± 0.77 versus 1.43 ± 0.87pg/mL, P<. 001; IL-8:
3.33 ±0.83 versus 2.86 ±0.76pg/mL, P<. 001).
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pregnant women and 116 nonpregnant women without
evidence of semen in vaginal secretions by acid phosphatase.
Pregnant women had signiﬁcantly higher concentrations of
SLPI compared to nonpregnant women (5.08 ± 0.43 versus
4.78 ± 0.52pg/mL; P<. 001). Among all subjects, SLPI
concentrationswereloweramongwomenwithBVcompared
to women without BV (4.80±0.53 versus 5.02±0.46pg/mL;
P = .002).
Inmultivariableanalyses,pregnancyremainedassociated
with increased concentrations of IL-8 (P<. 02) and SLPI
(P<. 001) after adjustment for BV, race, and age (Table 1).
Pregnancy was marginally associated with increased concen-
trations of IL-1β (P = .07) in the adjusted model. Similarly,
BV remained associated with increased concentrations of IL-
1β (P<. 001) and IL-8 (P = .04), and decreased SLPI
concentrations (P<. 001), after adjustment for pregnancy
status, race, and age.
4. Discussion
In this secondary analysis, pregnant women had increased
vaginalconcentrationsoftheproinﬂammatorycytokineIL-8
as well as the mucosal host defense molecule SLPI, regardless
of BV and other cofactors. In addition, we conﬁrmed
others’ ﬁndings that BV, regardless of pregnancy status, isJournal of Pregnancy 3
Table 1: Linear regression models∗ for the eﬀect of pregnancy and
bacterial vaginosis on log-transformed vaginal cytokine and SLPI
concentrations.
Coeﬃcient 95% Conﬁdence Interval P-value
Interleukin-1β
Pregnancy 0.199 (−0.019 to 0.416) .07
BV 0.763 (0.542 to 0.984) <.001
Interleukin-6
Pregnancy 0.025 (−0.139 to 0.189) .76
BV 0.125 (−0.041 to 0.291) .14
Interleukin-8
Pregnancy 0.255 (0.048 to 0.462) .02
BV 0.216 (0.006 to 0.426) .04
SLPI∗∗
Pregnancy 0.408 (0.280 to 0.537) <.001
BV −0.397 (−0.529 to −0.266) <.001
∗Models contain the analyte of interest as the dependent variable and
covariates for BV, pregnancy, race (as an indicator variable), and age (as a
continuous variable). ∗∗Restricted to women who were acid phosphatase
negative.
accompaniedbyincreasedvaginalproinﬂammatorycytokine
concentrationsalongwithdecreasedSLPIconcentrations[8–
10].
The primary limitation of this report is that it is a
secondary analysis of two diﬀerent study populations. A
second limitation is that missing data in the pregnancy
cohort required us to exclude a number of women from the
analysis. Much of the missing data was missing by design;
therefore, the exclusion of women with data missing by
design should not bias the results.
Taken together, these data suggest that BV should be
regarded as a proinﬂammatory condition for pregnant and
nonpregnant women. The vaginal inﬂammatory response
may be “on alert” in pregnancy, and antigenic stimulation
(suchasBV)appearstoresultinamoreexuberantinﬂamma-
tory response among pregnant, compared to nonpregnant
women. Moreover, we observed that SLPI concentrations are
greater in pregnant women compared to their nonpregnant
counterparts, regardless of BV status. Increased SLPI in the
context of pregnancy may be a physiologic host defense
mechanismtoprotectagainstascendinginfectionsthatcould
resultinpretermbirth.Furtherprospectivestudiesofvaginal
immunology are needed to help elucidate the eﬀects of
pregnancy, vaginal ﬂora and other factors on lower genital
tract host defenses and the implications for reproductive
health.
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